Andrew A. Krakauer
Known title: DirectorCIK: 0001302168
Andrew A. Krakauer's purchase track record
Andrew A. Krakauer has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/5/2025 | TFX | $115K | +8.6% | -10.3% | +9.8% |
| 11/30/2021 | TFX | $307K | +12.0% | -3.0% | -9.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TFX | ▲ Buy | Grant | 1,090 | $0 | 5/15/2026 | View on chart |
| TFX | ▲ Buy | Open Market | 1,000 | $115K | 8/5/2025 | View on chart |
| TFX | ▲ Buy | Grant | 1,051 | $0 | 5/9/2025 | View on chart |
| TFX | ▲ Buy | Grant | 649 | $0 | 5/7/2024 | View on chart |
| TFX | ▲ Buy | Grant | 527 | $0 | 5/9/2023 | View on chart |
| TFX | ▲ Buy | Grant | 399 | $0 | 5/3/2022 | View on chart |
| TFX | ▲ Buy | Open Market | 500 | $154K | 11/30/2021 | View on chart |
| TFX | ▲ Buy | Open Market | 500 | $154K | 11/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Teleflex Shares Lag Peers Amid Q2 Earnings and Value Debate
Teleflex (TFX) recently released its Q2 2026 earnings call transcript, which has fueled ongoing discussions about its valuation relative to peers like Sonovion. While some analysts highlight its status as a value stock, others have flagged concerns within the broader healthcare sector. The stock is currently trading near its 52-week low, reflecting a cautious market sentiment despite an average analyst target that remains significantly higher than the current price.
Teleflex Shares Lag Peers Amid Q2 Earnings and Value Debate. Teleflex (TFX) recently released its Q2 2026 earnings call transcript, which has fueled ongoing discussions about its valuation relative to peers like Sonovion. While some analysts highlight its status as a value stock, others have flagged concerns within the broader healthcare sector. The stock is currently trading near its 52-week low, reflecting a cautious market sentiment despite an average analyst target that remains significantly higher than the current price.